Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 20%
Hold 70%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc has demonstrated a consistent increase in earnings power over the past seven years, evidenced by rising EBITDA, a growing client base, and a reduction in headcount. The company benefits from positive trends in the healthcare market, as hospital executives report volumes exceeding budget expectations, which correlates with heightened demand for Health Catalyst's technology solutions. As the acute care market continues to recover from inflationary pressures and labor constraints, the outlook for revenue growth and improved margins appears favorable, further supporting a positive perspective on the company's financial trajectory.

Bears say

Health Catalyst Inc. has experienced a slowdown in total revenue growth, compounded by a highly penetrated total addressable market (TAM) among health systems, raising concerns regarding potential revenue and EBITDA decline in the coming years. The company's guidance for both 2025 and 2026 indicates a negative trend, with lower year-over-year revenue projections and a decrease in net dollar-based retention, suggesting challenges in maintaining existing client contracts. Additionally, pressures on margins, headwinds from Medicaid funding, and a changing hospital buying environment create further uncertainty for the company's financial outlook.

HCAT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 20% recommend Buy, 70% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 10 analysts, HCAT has a Hold consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.